# OnCo record daraxonrasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/daraxonrasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "daraxonrasib" ;
  schema:name "Daraxonrasib"@en ;
  schema:description "The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours."@en ;
  schema:url <https://onco.cc/drugs/daraxonrasib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma>, <https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220910Orig1s000ltr.pdf>, <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220910Orig1s000lbl.pdf>, <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22RASONQUE%22>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications>, <https://doi.org/10.1056/NEJMoa2605555>, <https://doi.org/10.1056/NEJMoa2505783> ;
  onco:status "approved" ;
  onco:modality "Small-molecule pan-RAS(ON) inhibitor" ;
  schema:alternateName "Rasonque" ;
  onco:approval "US 2026: Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or in adults who are not candidates for multiagent systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> ;
  onco:trials <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/nct07491445/>, <https://onco.cc/trials/nct07805954/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct06881784/>, <https://onco.cc/trials/nct06445062/>, <https://onco.cc/trials/nct07397338/>, <https://onco.cc/trials/nct06922591/>, <https://onco.cc/trials/nct05379985/>, <https://onco.cc/trials/nct06162221/>, <https://onco.cc/trials/nct06128551/>, <https://onco.cc/trials/nct07492680/>, <https://onco.cc/trials/codebreak-100/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/> .